1887

Abstract

The activity of voriconazole was compared with those of fluconazole and itraconazole against 270 clinical isolates of yeasts from the mouths of patients receiving palliative care for advanced cancer. A broth micro-dilution assay as described by the National Committee for Clinical Laboratory Standards was employed for determination of MICs. Of the 270 isolates, 206 (76 %) were fluconazole sensitive and 64 were fluconazole resistant. Voriconazole showed more potent activity than either fluconazole or itraconazole, including against some isolates resistant to both fluconazole and itraconazole. However, for fluconazole-resistant isolates, the MICs of itraconazole and voriconazole were proportionally higher than for the fluconazole-susceptible isolates, suggesting cross-resistance. Voriconazole may be a useful additional agent for the management of oral fungal infections caused by strains resistant to fluconazole and itraconazole, but susceptibility cannot be assumed and MIC determination is recommended prior to its use.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.45720-0
2005-10-01
2019-11-13
Loading full text...

Full text loading...

/deliver/fulltext/jmm/54/10/JM541009.html?itemId=/content/journal/jmm/10.1099/jmm.0.45720-0&mimeType=html&fmt=ahah

References

  1. Aldred, M. J., Addy, M., Bagg, J. & Finlay, I. ( 1991;). Oral health in the terminally ill: a cross-sectional pilot survey. Spec Care Dentist 11, 59–62.[CrossRef]
    [Google Scholar]
  2. Arias, A., Arevalo, M. P., Andreu, A., Rodriguez, C. & Sierra, A. ( 1996;). Candida glabrata: in vitro susceptibility of 84 isolates to eight antifungal agents. Chemotherapy 42, 107–111.[CrossRef]
    [Google Scholar]
  3. Bagg, J., Sweeney, M. P., Lewis, M. A. O., Jackson, M. S., Coleman, D., Al Mosaid, A., Baxter, W., McEndrick, S. & McHugh, S. ( 2003;). High prevalence of non-albicans yeasts and detection of anti-fungal resistance in the oral flora of patients with advanced cancer. Palliat Med 17, 477–481.[CrossRef]
    [Google Scholar]
  4. Berrouane, Y. F., Hollis, R. J. & Pfaller, M. A. ( 1996;). Strain variation among and antifungal susceptibilities of isolates of Candida krusei. J Clin Microbiol 34, 1856–1858.
    [Google Scholar]
  5. Clarke, J. G. M., Wilson, J., Von Haacke, N. P. & Milne, L. J. R. ( 1987;). Oral candidiasis in terminal illness. Health Bull (Edinb) 45, 268–271.
    [Google Scholar]
  6. Cross, L. J., Bagg, J., Oliver, D. & Warnock, D. ( 2000;). Serum itraconazole concentrations and clinical responses in Candida-associated denture stomatitis patients treated with itraconazole solution and itraconazole capsules. J Antimicrob Chemother 45, 95–99.
    [Google Scholar]
  7. Cuenca-Estrella, M., Díaz-Guerra, T. M., Mellado, E., Monzón, A. & Rodríguez-Tudela, J. L. ( 1999;). Comparative in vitro activity of voriconazole and itraconazole against fluconazole-susceptible and fluconazole-resistant clinical isolates of Candida species from Spain. Eur J Clin Microbiol Infect Dis 18, 432–435.[CrossRef]
    [Google Scholar]
  8. Davies, A. N., Brailsford, S., Broadley, K. & Beighton, D. ( 2002;). Oral yeast carriage in patients with advanced cancer. Oral Microbiol Immunol 17, 79–84.[CrossRef]
    [Google Scholar]
  9. Debruyne, D. ( 1997;). Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses. Clin Pharmacokinet 33, 52–77.[CrossRef]
    [Google Scholar]
  10. Donnelly, S. M., Sullivan, D. J., Shanley, D. B. & Coleman, D. C. ( 1999;). Phylogenetic analysis and rapid identification of Candida dubliniensis based on analysis of ACT1 intron and exon sequences. Microbiology 145, 1871–1882.[CrossRef]
    [Google Scholar]
  11. Finlay, I. G. ( 1986;). Oral symptoms and candida in the terminally ill. Br Med J (Clin Res Ed) 292, 592–593.[CrossRef]
    [Google Scholar]
  12. Hoffman, H. L. & Rathbun, R. C. ( 2002;). Review of the safety and efficacy of voriconazole. Expert Opin Investig Drugs 11, 409–429.[CrossRef]
    [Google Scholar]
  13. Jobbins, J., Bagg, J., Addy, M., Newcombe, R. G. & Finlay, I. G. ( 1992a;). Oral and dental disease in terminally ill cancer patients. BMJ 304, 1612. 1612.[CrossRef]
    [Google Scholar]
  14. Jobbins, J., Bagg, J., Parsons, K., Finlay, I., Addy, M. & Newcombe, R. G. ( 1992b;). Oral carriage of yeasts, coliforms and staphylococci in patients with advanced malignant disease. J Oral Pathol Med 21, 305–308.[CrossRef]
    [Google Scholar]
  15. Johnson, L. B. & Kauffman, C. A. ( 2003;). Voriconazole: a new triazole antifungal agent. Clin Infect Dis 36, 630–637.[CrossRef]
    [Google Scholar]
  16. Johnson, E. M., Warnock, D. W., Luker, J., Porter, S. R. & Scully, C. ( 1995;). Emergence of azole drug resistance in Candida species from HIV-infected patients receiving prolonged fluconazole therapy for oral candidosis. J Antimicrob Chemother 35, 103–114.[CrossRef]
    [Google Scholar]
  17. Laverdiere, M., Hoban, D., Restieri, C. & Habel, F. ( 2002;). In vitro activity of three new triazoles and one echinocandin against Candida bloodstream isolates from cancer patients. J Antimicrob Chemother 50, 119–123.[CrossRef]
    [Google Scholar]
  18. Lopez, J., Pernot, C., Aho, S., Caillot, D., Vagner, O., Dalle, F., Durnet-Archeray, M. J., Chavanet, P. & Bonnin, A. ( 2001;). Decrease in Candida albicans strains with reduced susceptibility to fluconazole following changes in prescribing policies. J Hosp Infect 48, 122–128.[CrossRef]
    [Google Scholar]
  19. NCCLS ( 1997;). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: Approved Standard. NCCLS document M27-A. Wayne, PA: National Committee for Clinical Laboratory Standards.
  20. Pelletier, R., Loranger, L., Marcotte, H. & de Carolis, E. ( 2002;). Voriconazole and fluconazole suceptibility of Candida isolates. J Med Microbiol 51, 479–483.
    [Google Scholar]
  21. Perfect, J. R., Marr, K. A., Walsh, T. J. & 8 other authors ( 2003;). Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 36, 1122–1131.[CrossRef]
    [Google Scholar]
  22. Purkins, L., Wood, N., Ghahramani, P., Greenhalgh, K., Allen, M. J. & Kleinermans, D. ( 2002;). Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother 46, 2546–2553.[CrossRef]
    [Google Scholar]
  23. Ramage, G. & López-Ribot, J. L. ( 2004;). Fungal biofilms and drug resistance. In Pathogenic Fungi: Host Interactions and Emerging Strategies for Control, chapter 11. Edited by G. San Blas & R. A. Calderone. Norwich: Horizon Scientific Press.
  24. Ramage, G., Van de Walle, K., Wickes, B. L. & López-Ribot, J. L. ( 2001;). A standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms. Antimicrob Agents Chemother 45, 2475–2479.[CrossRef]
    [Google Scholar]
  25. Rex, J. H., Pfaller, M. A., Walsh, T. J. & 8 other authors ( 2001;). Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev 14, 643–658.[CrossRef]
    [Google Scholar]
  26. Reynes, J., Bazin, C., Ajana, F., Datry, A., Le Moing, J. P., Chwetzoff, E. & Levron, J. C. ( 1997;). Pharmacokinetics of itraconazole (oral solution) in two groups of human immunodeficiency virus-infected adults with oral candidiasis. Antimicrob Agents Chemother 41, 2554–2558.
    [Google Scholar]
  27. Ruhnke, M., Schmidt-Westhausen, A. & Trautmann, M. ( 1997;). In vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection. Antimicrob Agents Chemother 41, 575–577.
    [Google Scholar]
  28. Sobel, J. D., Ohmit, S. E., Schuman, P., Klein, R. S., Mayer, K., Duerr, A., Vazquez, J. A. & Rampalo, A. ( 2001;). The evolution of Candida species and fluconazole susceptibility among oral and vaginal isolates recovered from human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women. J Infect Dis 183, 286–293.[CrossRef]
    [Google Scholar]
  29. Sweeney, M. P., Bagg, J., Baxter, W. P. & Aitchison, T. C. ( 1998;). Oral disease in terminally ill patients with xerostomia. Oral Oncol 34, 123–126.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.45720-0
Loading
/content/journal/jmm/10.1099/jmm.0.45720-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error